There is much excitement over the new checkpoint inhibitors, which have shown benefit across a variety of tumors. Right now, researchers are trying to define the subgroup of patients with breast cancer who might be most suited to checkpoint inhibitors, explained Lee Schwartzberg, MD, FACP, chief of Division of Hematology Oncology and professor of medicine at the University of Tennessee Health Science Center.
There is much excitement over the new checkpoint inhibitors, which have shown benefit across a variety of tumors. Right now, researchers are trying to define the subgroup of patients with breast cancer who might be most suited to checkpoint inhibitors, explained Lee Schwartzberg, MD, FACP, chief of Division of Hematology Oncology and professor of medicine at the University of Tennessee Health Science Center.
Transcript (slightly modified)
Are the results of trials evaluating the new checkpoint inhibitors in breast cancer encouraging?
There are trials evaluating the checkpoint inhibitors in breast cancer. We’re very excited about this group of agents, in general, which has shown benefit across a large variety of tumors. The data to date, in breast cancer, has been focused on metastatic disease and there are small populations, typically in phase 1 studies of the checkpoint inhibitors, the PD-1 inhibitors specifically, which have been reported.
The results show that there is some benefit in populations, particularly perhaps in the triple negative breast cancer population. The response rates seem a little bit lower than we see in some other diseases like lung cancer, and certainly lower than we see in a disease that’s very immune sensitive like melanoma. One of the hypotheses is that tumors that have large amount of genomic instability, lots of mutations like lung cancer, are more likely to respond to checkpoint inhibitors.
So part of the drive now in breast cancer is to define the subgroup of patients who might be most suited to checkpoint inhibitors. This is an area of very active discussion and investigation, and I think over the next year or 2 we’ll see much more about checkpoint inhibitors in metastatic breast cancer.
Navigating Sport-Related Neurospine Injuries, Surgery, and Managed Care
February 25th 2025On this episode of Managed Care Cast, we speak with Arthur L. Jenkins III, MD, FACS, CEO of Jenkins NeuroSpine, to explore the intersection of advanced surgical care for sport-related neurospine injuries and managed care systems.
Listen
Redefining Long COVID Care With Personalized Treatment
March 20th 2025To mark the 5-year anniversary of the COVID pandemic, The American Journal of Managed Care® spoke with Noah Greenspan, DPT, PT, CCS, EMT-B, cardiopulmonary physical therapist and director of the Pulmonary Wellness and Rehabilitation Center in New York City.
Read More
STEER Data Open Door to SMA Gene Therapy for Wider Age Range of Children
March 19th 2025Delivery of onasemnogene abeparvovec into the intrathecal space was safe and effective for children with spinal muscular atrophy (SMA) aged 2 to 17 years, who had previously been shut out of receiving gene therapy.
Read More